How compound registration impacts every stage of the DMTA cycle
Compound registration is a critical part of the drug discovery workflow. When chemical registration processes become slow, inconsistent, or difficult to scale, they create bottlenecks across the entire DMTA cycle. This guide explores the challenges facing modern discovery teams and the capabilities that today’s compound registration systems and compound management software need to support scientific data management at scale.
Key learning outcomes
- Why compound registration is critical to the DMTA cycle
- Common limitations of legacy compound registration systems
- How scientific data management impacts discovery productivity
- Best practices for chemical structure registration and duplicate detection
- Key capabilities of modern compound management software
- How scalable drug discovery data management supports better decision-making
- Emerging requirements for peptides, oligonucleotides, and other complex modalities
下载指南
Learn how modern compound registration systems help organizations improve data quality, support scientific collaboration, and accelerate discovery.
关于作者
Jan Christopherson – Senior Solutions Consultant
Jan Christopherson is a Senior Solutions Consultant working in Certara’s Discovery Portfolio. Following a stint at Mettler Toledo focused on laboratory instrument software interfacing and 21CFR compliant validation, he joined Chemaxon – acquired by Certara in 2025 – in 2019, where he has since supported customers through the full application portfolio and lifecycle.
